肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Immunology：热应激肿瘤细胞来源的外泌体可将Treg转化成Th17细胞从而发挥抗肿瘤作用

2017-12-09 MedSci MedSci原创

外泌体TregTh17
关注

含有丰富的热休克蛋白（HSP）70的热应激肿瘤细胞（HS-TEX）来源的外泌体可显著诱导机体的抗肿瘤免疫反应。HSP70诱导的白细胞介素-6（IL-6）促进IL-17的表达并引起前列腺肿瘤的排斥反应。然而，HS-TEXs是否可将调节性T细胞（Tregs）转化为Th17细胞而表现出抗肿瘤作用则尚不清楚。在这项研究中，我们发现，与TEXs相比，HS-TEXs能更有效地刺激树突状细胞分泌IL-6。在体外

含有丰富的热休克蛋白（HSP）70的热应激肿瘤细胞（HS-TEX）来源的外泌体可显著诱导机体的抗肿瘤免疫反应。HSP70诱导的白细胞介素-6（IL-6）促进IL-17的表达并引起前列腺肿瘤的排斥反应。然而，HS-TEXs是否可将调节性T细胞（Tregs）转化为Th17细胞而表现出抗肿瘤作用则尚不清楚。

在这项研究中，我们发现，与TEXs相比，HS-TEXs能更有效地刺激树突状细胞分泌IL-6。在体外，IL-6阻断肿瘤细胞来源的转化生长因子β1诱导的Treg分化并促进Th17细胞分化。 HS-TEXs具有很强的抗肿瘤作用，能将Tregs高效转化为Th17细胞，而这一过程完全依赖于IL-6。IL-17的中和完全消除了TEXs的抗肿瘤作用，但仅部分抑制了HS-TEXs的作用。此外，我们发现高温治疗的肿瘤患者血清中IL-6和IL-17的水平升高，外周血单个核细胞中Th17细胞增加，Tregs降低。

因此，我们的研究结果表明，HS-TEX可通过IL-6将免疫抑制性Treg转化成Th17细胞，从而发挥有效的抗肿瘤作用。

原始出处：

Guo D, Chen Y, et al., Exosomes from heat-stressed tumor cells inhibit tumor growth by converting regulatory T cells to Th17 cells via IL-6. Immunology. 2017 Dec 2. doi: 10.1111/imm.12874.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1312983, encodeId=a71c131298362, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413552, encodeId=58f2141355262, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445186, encodeId=08d8144518669, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477194, encodeId=ec1714e71947d, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-11 hmwwww

    #肿瘤细胞#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1312983, encodeId=a71c131298362, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413552, encodeId=58f2141355262, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445186, encodeId=08d8144518669, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477194, encodeId=ec1714e71947d, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-11 zhaojie88

    #Th17#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1312983, encodeId=a71c131298362, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413552, encodeId=58f2141355262, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445186, encodeId=08d8144518669, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477194, encodeId=ec1714e71947d, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-11 医者仁心

    #应激#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1312983, encodeId=a71c131298362, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413552, encodeId=58f2141355262, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445186, encodeId=08d8144518669, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477194, encodeId=ec1714e71947d, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Mon Dec 11 06:44:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-11 12498484m48(暂无昵称)

    #Treg#

    0

相关资讯

Sci Rep：Fe3O4@MPS@PMAC可灵敏富集糖肽并用于外泌体研究

生物样品中糖肽的低丰度使得在进一步分析之前需要富集它们。在本研究中，通过一步回流沉淀聚合法合成了高分子亲水性离子液体修饰的磁性（Fe3O4@MPS@PMAC）纳米粒子。由于聚合亲水性离子液体[2-（甲基丙烯酰氧基）乙基]三甲基氯化铵（MAC）具有优良的亲水性和对静电作用的强亲和力，所合成的Fe3O4@MPS@PMAC纳米粒子在糖肽富集中表现出优异的检测灵敏度（10fmol），较强的结合能力（100

PNAS：新型声学流体装置可快速高效分离外泌体

nanoparticles for the highly selective enrichment of N-linked glycopeptides. Sci Rep. 2017; 7: 6984.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539331/外泌体是在许多生物过程中发挥重要作用的纳米级细胞外囊泡，包括细胞间通讯、抗原呈递以及蛋白质、R

Cell Physiol Biochem：通过靶向CCNG2，外泌体miR-1246可促进乳腺癌的进展

乳腺癌的治疗仍然面临着巨大挑战挑战。本研究旨在验证外泌体microRNA-1246（miR-1246）作为乳腺癌的血清生物标志物，并了解乳腺癌进展的内在机制。采用实时定量PCR检测内源性和外源性miRNA的表达水平，使用Western blot检测目的蛋白的表达水平。使用扫描电镜和共聚焦显微镜来表征外泌体，并研究其摄取和转移。萤光素酶报告基因质粒及其突变体用于确认其靶目标。此外，通过侵袭测定和细胞

Ann Oncol：NSCLC患者使用外泌体RNA联合循环肿瘤DNA可改善体细胞突变的检测结果

使用循环肿瘤DNA（ctDNA）来检测体细胞突变的主要局限性在于一部分癌症患者的ctDNA水平较低。本研究探究了exosomal RNA（exoRNA）和无细胞DNA（cfDNA）联合分离是否可以改善用于检测NSCLC患者EGFR突变的血液液态活检效果。研究纳入了在TIGER-X（NCT01526928）登记的84名患者，收集预处理肿瘤和血浆样本。分离exoRNA和cfDNA（exoNA）以分析突

Oncotarget：外泌体miR-141-3p可调节成骨细胞活性来促进前列腺癌的进展

来自于癌细胞的外泌体，含有微小RNA，且先于癌细胞到达转移部位。既往研究已经显示外泌体miR-141-3p与转移性前列腺癌（PCa）的发生相关。然而，miR-141-3p在骨转移微环境中的作用和调控机制有待于进一步的研究。在这项研究中，研究人员进行了一系列的体内和体外实验，以确定来自MDA PCa 2b细胞的外来体miR-141-3p是否可调节成骨细胞的活性以促进成骨细胞的转移。研究人员从细胞培养

Macromol Biosci：外泌体修饰的组织工程血管可实现内皮祖细胞的捕获和siRNA的靶向递送

不稳定和较差的靶向性是导致RNA修饰的组织工程血管（TEBV）长期效果较差的主要原因。 可以在外泌体中富集RNA，然后将其递送到靶细胞中，而外泌体修饰的TEBV是否实现RNA的靶向递送目前尚不清楚。本研究中，为了促进间质干细胞（MSC）来源的外泌体上klotho蛋白的表达，首先将klotho质粒转染到MSsC中，然后使用电穿孔方法将腺苷激酶（ADK）siRNA加载到外泌体（klotho/ADK s